Gross-Goupil, M <br/><br/>
Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  12 2018 
 - 2371-2378 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdy454  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Aged<br/>Antineoplastic Agents--administration & dosage<br/>Axitinib--administration & dosage<br/>Carcinoma, Renal Cell--mortality<br/>Chemotherapy, Adjuvant--methods<br/>Disease-Free Survival<br/>Double-Blind Method<br/>Drug Administration Schedule<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Intention to Treat Analysis<br/>Kidney Neoplasms--mortality<br/>Male<br/>Middle Aged<br/>Neoplasm Recurrence, Local--mortality<br/>Nephrectomy<br/>Placebos--administration & dosage